Glycyx Alternatives & Competitors
12 companies similar to Glycyx — Restoring immune response in cancer: reversing Opioid-Induced Immunodeficiency t...
Companies similar to Glycyx
iOmx Therapeutics AG
Developing next-generation targeted cancer immunotherapy treatments
Germany
3T Biosciences
3T is an immunotherapy company developing next-generation, transformative therapies for br...
South San Francisco, Unit...
Onchilles Pharma
Developing drug candidates that have the potential to be broadly effective against a wide...
San Diego, United States
Xilio Therapeutics, Inc.
Focused on harnessing the immune system to achieve deep and durable clinical responses to...
Waltham, United States
Rival Readout
Competing with Glycyx? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Arcellx
Arcellx is a clinical-stage biotechnology company based in Redwood City, California
Redwood City, United Stat...
Kestrel Therapeutics
We aspire to invent brilliant technologies for difficult cancer targets, beginning with mu...
Watertown, United States
Mustang Bio
A fortress biotech Company
Waltham, United States
Incyclix Bio
Regaining Cell Cycle Control
Durham, United States
Bicara Therapeutics
Pioneering bifunctional antibodies for targeted tumor modulation
Boston, United States
Macomics
Macrophage Biology Revealed:Developing breakthrough approaches to macrophage activity to c...
Edinburgh, United Kingdom
Adaptimmune
Designing and delivering cell therapies to transform the lives of people with cancer.
Abingdon, United Kingdom
About Glycyx
Glycyx, a highly innovative biotech firm founded in 2020 and headquartered in the United States, is tackling a critical yet often overlooked challenge in cancer treatment—opioid-induced immunodeficiency that diminishes the efficacy of immunotherapy. Known as Opioid-Induced Immunotherapy Failure (OIIF), this condition i...
Development of therapies that restore immune function, Combination treatments with immune checkpoint inhibitors, Enhanced T-cell infiltration into tumors, Inhibition of opioid-induced immune suppression
Cancer patients, Healthcare providers, Oncologists, Pharmaceutical companies
Cancer Treatment, Immunotherapy, Opioid-Induced Immunodeficiency, Immune Checkpoint Inhibitors, Peripherally Restricted Opioid Antagonist, Phase 2 Clinical Trials, Tumor Microenvironment, Non-Small Cell Lung Cancer, Head And Neck Cancer, Hepatocellular Cancer, Immuno-oncology, Therapeutics, Oncology, Clinical Development
B2B, B2D
Licensing, Product Sales
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Glycyx: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Glycyx on 11 Mar 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 3 Jul 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
